Perspective Therapeutics, Inc. (CATX) stock
CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.75−0.03 (-3.85%)
Close on Nov 20, 2026Market cap $86.05MP/E –Yield –
Perspective Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Perspective Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$125.23M. For fiscal 2025 it was -$113.56M. The highest annual figure on record is -$2.96M in fiscal 2011.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$113.56M | – |
| FY2024 | Dec 31, 2024 | -$90.89M | – |
| FY2022 | Jun 30, 2022 | -$6.42M | – |
| FY2021 | Jun 30, 2021 | -$3.45M | – |
| FY2020 | Jun 30, 2020 | -$3.48M | – |
| FY2019 | Jun 30, 2019 | -$5.25M | – |
| FY2018 | Jun 30, 2018 | -$6.73M | – |
| FY2017 | Jun 30, 2017 | -$6.31M | – |
| FY2016 | Jun 30, 2016 | -$5.08M | – |
| FY2015 | Jun 30, 2015 | -$4.34M | – |
| FY2014 | Jun 30, 2014 | -$4.59M | – |
| FY2013 | Jun 30, 2013 | -$4.07M | – |
| FY2012 | Jun 30, 2012 | -$3.60M | – |
| FY2011 | Jun 30, 2011 | -$2.96M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$29.26M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$28.28M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$39.83M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$27.86M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$24.04M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$21.83M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$44.98M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$18.63M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$14.26M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$13.01M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$2.11M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$1.38M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$1.64M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$2.27M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$1.09M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$766.00K | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$873.00K | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$714.00K | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$1.19M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$548.00K | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$903.00K | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$836.00K | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -$1.14M | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -$1.16M | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -$1.43M | – |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -$1.52M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$2.37M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$1.34M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$1.47M | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$1.55M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$1.86M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$1.39M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$1.48M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$1.58M | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$1.25M | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$1.33M | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | -$1.41M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | -$1.09M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | -$1.10M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | -$1.05M | – |
See a number that looks wrong?